摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Methyl-4,5-bis-imidazol | 30450-41-0

中文名称
——
中文别名
——
英文名称
2-Methyl-4,5-bis-imidazol
英文别名
4,5-bis-(4-chloro-phenyl)-2-methyl-1H-imidazole;4,5-bis(4-chlorophenyl)-2-methyl-1H-imidazole
2-Methyl-4,5-bis<p-chlor-phenyl>-imidazol化学式
CAS
30450-41-0
化学式
C16H12Cl2N2
mdl
——
分子量
303.191
InChiKey
IIZZQXAUYMDYGU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    28.7
  • 氢给体数:
    1
  • 氢受体数:
    1

文献信息

  • [EN] SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS<br/>[FR] IMIDAZOLES SUBSTITUES SERVANT DE MODULATEURS DE RECEPTEURS DE CANNABINOIDES
    申请人:MERCK & CO INC
    公开号:WO2003007887A2
    公开(公告)日:2003-01-30
    The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1)receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Novel compounds of structural formula (I) are also claimed.
查看更多